EDITORIAL

RNA methylation as a leukemia stem cell vulnerability

Fengbiao Zhou

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany

Correspondence: F. Zhou
Fengbiao.Zhou@med.uni-heidelberg.de

Received: April 15, 2026.
Accepted: April 23, 2026.
Early view: April 30, 2026.

https://doi.org/10.3324/haematol.2026.301076

©2026 Ferrata Storti Foundation
Published under a CC BY-NC license

In this issue of *Haematologica*, Zhou *et al*. report that the RNA 5-methylcytosine (m^5C) methyltransferase NSUN2 is selectively required for leukemia stem cell (LSC) maintenance while being largely dispensable for normal hematopoiesis.[1] Using complementary human and murine acute myeloid leukemia (AML) models, the authors demonstrated that NSUN2 sustains leukemic stemness through an m^5C-dependent regulatory axis involving FOSB and BCL2L1. These findings identify RNA cytosine methylation as a context-specific vulnerability in AML and highlight the growing importance of epitranscriptomic regulation in hematologic malignancies.

AML is organized as a cellular hierarchy in which a rare population of LSC drives disease propagation and relapse.[2] While conventional therapies often eliminate bulk leukemic blasts, LSC frequently survive treatment and regenerate the disease. Identifying molecular dependencies that distinguish LSC from normal hematopoietic stem cells therefore remains a major therapeutic goal. However, because these populations share many transcriptional and epigenetic features, defining selective vulnerabilities has proven challenging.

Over the past decade, studies of chromatin regulators and DNA methylation pathways have revealed critical epigenetic dependencies in AML. More recently, RNA modifications have emerged as an additional regulatory layer shaping gene expression.[3] Chemical modifications on RNA can influence RNA stability, translation, and cellular stress responses, thereby controlling gene expression programs essential for stem cell function. Among these modifications, N^6-methyladenosine (m^6A) has been most extensively studied in leukemia. Components of the m^6A machinery, including METTL3, FTO, and ALKBH5, have been shown to regulate leukemic proliferation and LSC self-renewal, establishing RNA modifications as functional drivers of leukemogenesis.[4-6] The study by Zhou *et al*. extends this paradigm by focusing on RNA cytosine methylation. NSUN2 catalyzes m^5C modification across multiple RNA species, including transfer RNA and messenger RNA, and has been implicated in RNA stability and translational control. Through inducible knockout models, the authors demonstrated that NSUN2 is required for leukemia maintenance across multiple AML contexts. Deletion of Nsun2 markedly reduces LSC frequency and impairs leukemic propagation, whereas normal hematopoietic stem and progenitor cells show minimal dependence on NSUN2. This differential requirement between malignant and normal stem cells suggests a potential therapeutic window. Mechanistically, the authors provide evidence that NSUN2 promotes m^5C modification within the 3' untranslated region of FOSB mRNA, enhancing its expression and sustaining downstream BCL2L1-mediated survival signaling. Although further work will be needed to fully define NSUN2 RNA targets and the dynamics of m^5C deposition, this NSUN2–FOSB–BCL2L1 axis illustrates how RNA modifications can stabilize oncogenic programs at the post-transcriptional level.

The broader significance of this work lies in the expanding landscape of RNA modifications in leukemia biology (Table 1). In addition to m^6A and m^5C, RNA editing mediated by ADAR enzymes and alterations in ribosomal RNA modifications

Table 1. RNA modifications implicated in acute myeloid leukemia.

RNA modification	Key enzymes	Functional relevance in AML
m^6A (N^6-methyladenosine)	METTL3, METTL14, FTO, ALKBH5	Controls leukemic proliferation and LSC maintenance
m^5C (5-methylcytosine)	NSUN2, DNMT2	Supports LSC survival and RNA stability
A-to-I RNA editing	ADAR1	Promotes LSC and immune signaling regulation
rRNA 2′-O-methylation	Fibrillarin (FBL)	Alters ribosome function and translational control in leukemia

AML: acute myeloid leukemia; LSC: leukemia stem cells.




Figure 1. A selective epitranscriptomic vulnerability in leukemia stem cells. The study by Zhou *et al*. identifies NSUN2-mediated m^5C methylation as a selective vulnerability in leukemia stem cells. NSUN2 deposits m^5C on the 3′ untranslated region of *FOSB* mRNA to increase its stability and expression, while FOSB transcriptionally activates *NSUN2*, forming a positive feedback loop that sustains leukemic stemness but is largely dispensable for normal hematopoiesis.

have also been implicated in malignant hematopoiesis.[7,8] For example, changes in ribosomal RNA 2'-O-methylation can influence ribosome function and translational control, further linking RNA chemical diversity to leukemic transformation. Together, these findings suggest that multiple layers of RNA modification contribute to regulatory networks sustaining LSC.

Why LSC may be particularly dependent on RNA modification pathways remains an open question. Leukemic cells may experience heightened proliferative and metabolic stress, increasing reliance on mechanisms that stabilize RNA and optimize translation. Alternatively, normal hematopoietic stem cells may possess compensatory pathways that buffer against disruption of individual RNA modifiers. Clarifying these differences will be important for determining whether RNA methylation dependencies are broadly shared across AML subtypes or restricted to specific genetic contexts.

The work by Zhou *et al*. highlights the expanding role of RNA modifications in leukemia biology. As the field of epitranscriptomics continues to evolve, defining context-specific dependencies such as NSUN2 may provide new insights into LSC regulation and potential therapeutic strategies.

Disclosures

No conflicts of interest to disclose.

References

1. Zhou B, Yuan Y, Cai Y, et al. NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expression. Haematologica. 2026;111(10):3276-3291.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.
3. Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169(7):1187-1200.
4. Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 2017;552(7683):126-131.
5. Li ZJ, Weng HY, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 2017;31(1):127-141.
6. Shen C, Sheng Y, Zhu AC, et al. RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell. 2020;27(1):64-80.e9.
7. Zipeto MA, Court AC, Sadarangani A, et al. ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis. Cell Stem Cell. 2016;19(2):177-191.
8. Zhou FB, Aroua N, Liu Y, et al. A dynamic rRNA ribomethylome drives stemness in acute myeloid leukemia. Cancer Discov. 2023;13(2):332-347.